Evgen Pharma (LON:EVG)‘s stock had its “corporate” rating reaffirmed by research analysts at FinnCap in a research report issued to clients and investors on Thursday, ThisIsMoney.Co.Uk reports.
LON:EVG opened at GBX 20 ($0.26) on Thursday. The company has a market capitalization of $26.53 million and a P/E ratio of -6.67. Evgen Pharma has a 1-year low of GBX 13.10 ($0.17) and a 1-year high of GBX 33 ($0.43).
Evgen Pharma Company Profile
Evgen Pharma plc, a clinical stage drug development company, focuses on the treatment of cancer and neurological diseases. Its core technology is Sulforadex, which include synthetic and stabilized analogues of the naturally occurring compound sulforaphane. The company's lead product is SFX-01, a synthetic version of sulforaphane stabilised that is in Phase II clinical trials for the treatment of breast cancer and subarachnoid haemorrhage, as well as in preclinical stage for multiple sclerosis and clinical stage to treat prostate cancer.
Receive News & Ratings for Evgen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evgen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.